Impact of malignant stem cell burden on therapy outcome in newly diagnosed chronic myeloid leukemia patients (Q45340032)

13 December 2017

title

Impact of malignant stem cell burden on therapy outcome in newly diagnosed chronic myeloid leukemia patients (English)

1 reference

13 December 2017

main subject

chronic myeloid leukemia

0 references

1 reference

1

1 reference

13 December 2017

4

1 reference

13 December 2017

5

1 reference

13 December 2017

K Porkka

20

0 references

Bjørn Tore Gjertsen

7

object named as

B T Gjertsen

1 reference

13 December 2017

J Richter

2

1 reference

13 December 2017

G Barbany

3

1 reference

13 December 2017

T Gedde-Dahl

6

1 reference

13 December 2017

R Hovland

8

1 reference

13 December 2017

S Hernesniemi

9

1 reference

13 December 2017

D Josefsen

10

1 reference

13 December 2017

P Koskenvesa

11

1 reference

13 December 2017

I Dybedal

12

1 reference

13 December 2017

B Markevärn

13

1 reference

13 December 2017

T Olofsson

14

1 reference

13 December 2017

U Olsson-Strömberg

15

1 reference

13 December 2017

K Rapakko

16

1 reference

13 December 2017

S Thunberg

17

1 reference

13 December 2017

L Stenke

18

1 reference

13 December 2017

B Simonsson

19

1 reference

13 December 2017

H Hjorth-Hansen

21

1 reference

13 December 2017

Nordic CML Study Group (NCMLSG)

22

1 reference

13 December 2017

publication date

18 January 2013

1 reference

13 December 2017

1 reference

13 December 2017

volume

27

1 reference

13 December 2017

issue

7

1 reference

13 December 2017

page(s)

1520-1526

1 reference

Seeking the causes and solutions to imatinib-resistance in chronic myeloid leukemia

13 December 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.19

Efficacy and safety of dasatinib in imatinib-resistant or -intolerant patients with chronic myeloid leukemia in blast phase.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.19

Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.19

Dasatinib induces durable cytogenetic responses in patients with chronic myelogenous leukemia in chronic phase with resistance or intolerance to imatinib.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.19

Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.19

Nilotinib in patients with Ph+ chronic myeloid leukemia in accelerated phase following imatinib resistance or intolerance: 24-month follow-up results

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.19

Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.19

Evolving treatment strategies for patients newly diagnosed with chronic myeloid leukemia: the role of second-generation BCR-ABL inhibitors as first-line therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.19

Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.19

Dasatinib (BMS-354825) targets an earlier progenitor population than imatinib in primary CML but does not eliminate the quiescent fraction

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.19

Insights into the stem cells of chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.19

Chronic myeloid leukemia stem cells possess multiple unique features of resistance to BCR-ABL targeted therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.19

Chronic myeloid leukemia stem cells are not dependent on Bcr-Abl kinase activity for their survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.19

Human chronic myeloid leukemia stem cells are insensitive to imatinib despite inhibition of BCR-ABL activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.19

Critical molecular pathways in cancer stem cells of chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.19

Persistence of malignant hematopoietic progenitors in chronic myelogenous leukemia patients in complete cytogenetic remission following imatinib mesylate treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.19

Persistence of leukemia stem cells in chronic myelogenous leukemia patients in prolonged remission with imatinib treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.19

Chronic myelogenous leukemia stem and progenitor cells demonstrate chromosomal instability related to repeated breakage-fusion-bridge cycles mediated by increased nonhomologous end joining

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.19

Detection of BCR-ABL kinase mutations in CD34+ cells from chronic myelogenous leukemia patients in complete cytogenetic remission on imatinib mesylate treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.19

Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.19

Purification of primitive human hematopoietic cells capable of repopulating immune-deficient mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.19

Different subsets of primary chronic myeloid leukemia stem cells engraft immunodeficient mice and produce a model of the human disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.19

Standardized definitions of molecular response in chronic myeloid leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.19

Low or undetectable numbers of Philadelphia chromosome-positive leukemic stem cells (Ph(+)CD34(+)CD38(neg)) in chronic myeloid leukemia patients in complete cytogenetic remission after tyrosine kinase inhibitor therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.19

Residual normal stem cells can be detected in newly diagnosed chronic myeloid leukemia patients by a new flow cytometric approach and predict for optimal response to imatinib.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.19

Isolation and killing of candidate chronic myeloid leukemia stem cells by antibody targeting of IL-1 receptor accessory protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.19

Persistent malignant stem cells in del(5q) myelodysplasia in remission

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.19

CXCR4 up-regulation by imatinib induces chronic myelogenous leukemia (CML) cell migration to bone marrow stroma and promotes survival of quiescent CML cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.19

Bone marrow mesenchymal stromal cells non-selectively protect chronic myeloid leukemia cells from imatinib-induced apoptosis via the CXCR4/CXCL12 axis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.19

Evaluation of residual CD34(+) Ph(+) progenitor cells in chronic myeloid leukemia patients who have complete cytogenetic response during first-line nilotinib therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.19

Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukaemia: 24-month minimum follow-up of the phase 3 randomised ENESTnd trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.19

Granulocyte-macrophage progenitors as candidate leukemic stem cells in blast-crisis CML

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.19

CD34+/Ph+ cells are still detectable in chronic myeloid leukemia patients with sustained and prolonged complete cytogenetic remission during treatment with imatinib mesylate

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.19

21 January 2018

Identifiers

DOI

10.1038/LEU.2013.19

1 reference

Dimensions Publication ID

13 December 2017

1037478860

0 references

1 reference